Bosna Hersek - Hırvatça - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

novartis ba d.o.o. - финголимод - kapsula, tvrda - 0.5 mg/1 kapsula - 1 kapsula, tvrda sadrži: 0, 5 mg fingolimod (u obliku fingolimod hidrohlorida)

Bosna Hersek - Hırvatça - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - Бисопролол - film tableta - 10 mg/1 tableta - 1 film tableta sadrži: 10 mg bisoprolola

Bosna Hersek - Hırvatça - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - Бисопролол - film tableta - 5 mg/1 tableta - 1 film tableta sadrži: 5 mg bisoprolola

Avrupa Birliği - Hırvatça - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomide - multipla skleroza - selektivni imunosupresivi - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Avrupa Birliği - Hırvatça - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - multipla skleroza - selektivni imunosupresivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Bosna Hersek - Hırvatça - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

sanofi d.o.o. - teriflunomid - film tableta - 14 mg/1 tableta - 1 film tableta sadrži: 14 mg teriflunomida

Bosna Hersek - Hırvatça - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

medis international d.o.o. sarajevo - natalizumab - koncentrat za rastvor za infuziju - 300 mg/15 ml - 1 bočica sa 15 ml koncetrata za rastvor za infuziju sadrži: 300 mg natalizumaba

Bosna Hersek - Hırvatça - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

amicus pharma d.o.o. - teriflunomid - film tableta - 14 mg/1 tableta - 1 film tableta sadrži: 14 mg teriflunomida

Avrupa Birliği - Hırvatça - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Avrupa Birliği - Hırvatça - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivima selektivni imunosupresivima - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).